HARROW, INC. (HROW): Completion of Acquisition or Disposition of Assets
HARROW, INC. (HROW) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Harrow Closes Acquisition of TYRVAYA® First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow’s Growing Ocular Surface Franchise NASHVILLE, Tenn., October 5, 2026 — Harrow (Nasdaq: HROW), a leading provi
How this was made
The 30-second read
Why it matters
The acquisition positions Harrow with two distinct dry‑eye therapies, potentially increasing cross‑selling opportunities and market share.
Market read
First‑report 8‑K filing of a $30M cash acquisition with up‑to‑$100M total consideration, likely moving HROW stock.
What to watch
Milestone payments are contingent on sales; actual revenue contribution may be slower than projected.
Background
Harrow (Nasdaq:HROW) focuses on ophthalmic disease management and recently launched VEVYE for dry eye.
Ticker impact
Harrow announced closing its acquisition of TYRVAYA nasal spray from Viatris, paying $30M cash with up to $70M milestones.
upward pressure as investors price in new product revenue and pipeline expansion
Acquisition adds a FDA‑approved therapy and experienced sales force, increasing future sales visibility.
Market effects
Strengthens the ophthalmology/ocular‑surface sector with a new dry‑eye treatment.
U.S. market sees added exposure to dry‑eye therapeutics; limited impact outside North America.
Modest, as the product is approved in U.S., China and Taiwan only.
Counterpoint
If integration costs exceed expectations, the acquisition could dilute margins.
Key entities
- partnerViatris Inc.
Seller of TYRVAYA rights, retaining Japan commercialization.
